What is the recommended diagnostic work‑up and treatment strategy for paraneoplastic autoimmune encephalitis?

Paraneoplastic Autoimmune Encephalitis: Diagnostic Work-Up and Treatment Strategy

Immediate Diagnostic Approach

Start high-dose intravenous methylprednisolone immediately after basic CSF analysis excludes infection, even before antibody results return, because clinical suspicion alone justifies treatment and delays worsen outcomes. 1, 2, 3

Essential Initial Testing

Perform these investigations simultaneously to avoid treatment delays:

• Brain MRI and EEG to identify focal or multifocal abnormalities supporting autoimmune encephalitis 1, 3
• Lumbar puncture to confirm inflammation, exclude infection/malignancy, and test CSF for oligoclonal bands, IgG index, IgG synthesis rate, and neuronal autoantibodies 1, 3
• Serum neuronal autoantibody panels sent in parallel with CSF testing to maximize diagnostic yield 1, 3
• Brain FDG-PET when clinical suspicion remains high but MRI/EEG/CSF are nondiagnostic 1, 3

Cancer Screening Protocol

All patients require contrast-enhanced CT of chest, abdomen, and pelvis as the initial cancer screening study. 1, 2, 3

Additional imaging based on antibody profile and risk factors:

• Pelvic ultrasound (transvaginal in females, testicular in males) for young and middle-aged adults to detect teratoma 2
• Mammogram (add breast MRI if high suspicion) for females not up-to-date with screening or with strong family history 2
• Whole-body FDG-PET when initial CT is negative but malignancy suspicion persists based on smoking history, advanced age, or specific antibody pattern 1, 2, 3
• Pelvic MRI if ultrasound is equivocal for teratoma 2

First-Line Immunotherapy Algorithm

Standard Presentation

High-dose intravenous methylprednisolone is the preferred first-line agent unless contraindicated by uncontrolled hypertension, uncontrolled diabetes, active peptic ulcer, or severe behavioral symptoms that worsen with corticosteroids. 1, 2, 3

If steroids are contraindicated, use IVIG or plasma exchange as alternative first-line agents. 1, 3

Severe Presentation Requiring Upfront Combination

For severe disease—new-onset refractory status epilepticus, severe dysautonomia, ICU admission, or severe NMDAR-antibody encephalitis—combine corticosteroids with IVIG or plasma exchange from the outset rather than sequentially. 1, 2, 3

Choose between IVIG and plasma exchange based on these factors:

• IVIG is favored for agitated patients or those with bleeding disorders 1, 2, 3
• Plasma exchange (5–10 sessions every other day) is preferred for severe hyponatremia, high thromboembolic risk (known/suspected cancer, smoking, hypertension, diabetes, hyperlipidemia, hypercoagulable states), or concurrent demyelinating disease 1, 2, 3
• Retrospective data show plasma exchange added to corticosteroids yields greater Modified Rankin Scale improvement than corticosteroids alone 2

Escalation for Non-Responders

If no clinical, radiological, or electrophysiological improvement occurs by the end of the initial treatment cycle, add IVIG or plasma exchange to the corticosteroid regimen. 1, 2, 3

Expert consensus shows 62% of clinicians add a different first-line therapy when the initial agent fails, whereas only 26% proceed directly to second-line agents. 2

Second-Line Immunotherapy

Initiate second-line agents 2–4 weeks after completing combined first-line therapy if no meaningful clinical or radiological improvement has occurred. 1, 2, 3

In severe or refractory cases, some clinicians start second-line therapy earlier (approximately 2 weeks after first-line initiation). 2

Agent Selection Based on Antibody Type

The choice between rituximab and cyclophosphamide depends critically on whether the antibody targets intracellular or cell-surface antigens:

• Rituximab is the preferred second-line agent (chosen by ~80% of experts) for antibody-mediated autoimmunity targeting cell-surface antigens (e.g., NMDAR, LGI1); it is less toxic than cyclophosphamide and specifically targets antibody production 1, 2, 3

  • Typical dosing: 375 mg/m² weekly for 4 weeks or two 1000 mg infusions given 2 weeks apart 2

• Cyclophosphamide (600–1000 mg/m²) is reserved for classical paraneoplastic syndromes with intracellular antibodies (e.g., anti-Hu, anti-Yo, anti-CRMP5) because these reflect cell-mediated autoimmunity 1, 2, 3, 4

Refractory Disease

For cases unresponsive to rituximab or cyclophosphamide, consider tocilizumab (IL-6 inhibitor) or bortezomib (proteasome inhibitor), acknowledging that supporting evidence is limited. 1, 2, 3

Bridging and Maintenance Therapy

After acute immunotherapy, initiate bridging therapy with a gradual oral prednisone taper, monthly IVIG, or monthly intravenous methylprednisolone to maintain disease control. 2, 3

Long-term maintenance is generally unnecessary except in patients with particularly severe or prolonged disease courses. 2

Critical Pitfalls to Avoid

Do not delay immunotherapy while awaiting antibody confirmation; clinical suspicion alone justifies immediate treatment because outcomes worsen with delays. 2

Recognize that intracellular antibodies (anti-Hu, anti-Ta/Ma2, anti-Yo) are more strongly associated with underlying malignancy (lung, testis, breast, gynecologic, neuroendocrine cancers) and typically respond poorly to immunotherapy compared to cell-surface antibodies. 4, 5

Be aware that false-positive antibody results occur in 61.8% of positive tests, with 95.2% of false positives occurring in serum-only testing—always correlate antibody results with clinical phenotype and supportive paraclinical investigations. 6

Tumor removal is the most important treatment for paraneoplastic encephalitis with intracellular antibodies and has more effect on neurological outcome than immunomodulation alone. 7, 5

Prognosis and Relapse

Relapse occurs in 10–30% of patients, most commonly within the first two years after onset; the 2-year relapse risk is approximately 12%, and about two-thirds of relapses are milder than the initial episode. 2

Patients with anti-Hu antibodies usually have small-cell lung cancer (94%), multifocal neurological symptoms (78%), and poor neurological outcomes. 5

Patients with anti-Ta (anti-Ma2) antibodies are typically young men with testicular tumors (100%), frequent hypothalamic involvement (70%), and poor neurological outcomes. 5